Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | BRAF | P15056 | 6/20 | 0.51 |
| ▸ | FAM20C | Q8IXL6 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.45 |
| ▸ | IGF1R | P08069 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | INSR | P06213 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | TEK | Q02763 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9972586 | 0.82 | PIK3CA (0.51) | BRAFMAPK1PIK3CAPTK2IGF1R | |
| SCHEMBL4348610 | 0.80 | BRAF (0.62) | BRAFPDGFRBPDGFRAMAPK1PIK3CA | |
| SCHEMBL4349785 | 0.80 | MEN1 (0.60) | MEN1KMT2ABRAFMAPK1PIK3CA | |
| SCHEMBL9972585 | 0.79 | SLC2A1 (0.47) | BRAFMAPK1PIK3CAPTK2IGF1R | |
| SCHEMBL6979115 | 0.79 | FAM20C (0.70) | FAM20CPTK2IGF1REGFRINSR | |
| SCHEMBL4350968 | 0.78 | BRAF (0.54) | BRAFPDGFRBPDGFRAMAPK1PIK3CA | |
| SCHEMBL9972584 | 0.77 | PIK3CA (0.57) | BRAFPDGFRBPDGFRAMAPK1PIK3CA | |
| SCHEMBL4358596 | 0.77 | BRAF (0.51) | MEN1KMT2ABRAFPDGFRBPDGFRA | |
| SCHEMBL4350972 | 0.76 | PIK3CA (0.52) | BRAFPDGFRBPDGFRAMAPK1PIK3CA | |
| SCHEMBL4349295 | 0.76 | AAK1 (0.52) | MEN1KMT2AMAPK1PIK3CAMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275534-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | ZENTARIS GMBH (DE) | 2009-11-05 | — | — | US | claimed |
| US-8604196-B2 | Modulating signal transduction pathways with 1-ethyl-3-[3-(1-methyl-1H-pyrazol-4-yl)-pyrido[2.3-B]pyrazine-6-yl]thiourea | AETERNA ZENTARIS GMBH (DE) | 2013-12-10 | — | — | US | disclosed |
| US-8536332-B2 | Modulating signal transduction pathways with substituted pyridol [2,3-b] pyrazines | AETERNA ZENTARIS GMBH (DE) | 2013-09-17 | — | — | US | disclosed |
| US-8536332-B2 | Modulating signal transduction pathways with substituted pyridol [2,3-b] pyrazines | AETERNA ZENTARIS GMBH (DE) | 2013-09-17 | — | — | US | disclosed |
| US-8536332-B2 | Modulating signal transduction pathways with substituted pyridol [2,3-b] pyrazines | AETERNA ZENTARIS GMBH (DE) | 2013-09-17 | — | — | US | disclosed |
| US-8507486-B2 | Pyridopyrazine derivatives, process of manufacturing and uses thereof | AETERNA ZENTARIS GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| US-8507486-B2 | Pyridopyrazine derivatives, process of manufacturing and uses thereof | AETERNA ZENTARIS GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| US-8507486-B2 | Pyridopyrazine derivatives, process of manufacturing and uses thereof | AETERNA ZENTARIS GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| US-20120277219-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | AETERNA ZENTARIS GMBH (DE) | 2012-11-01 | — | — | US | disclosed |
| US-20120277219-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | AETERNA ZENTARIS GMBH (DE) | 2012-11-01 | — | — | US | disclosed |
| US-20120209050-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | AETERNA ZENTARIS GMBH (DE) | 2012-08-16 | — | — | US | disclosed |
| US-20120209050-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | AETERNA ZENTARIS GMBH (DE) | 2012-08-16 | — | — | US | disclosed |
| US-20120209050-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | AETERNA ZENTARIS GMBH (DE) | 2012-08-16 | — | — | US | disclosed |
| US-8202883-B2 | Substituted pyrido[2,3-b]pyrazine compounds as modulators of tyrosine kinases | AETERNA ZENTARIS GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8202883-B2 | Substituted pyrido[2,3-b]pyrazine compounds as modulators of tyrosine kinases | AETERNA ZENTARIS GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8202883-B2 | Substituted pyrido[2,3-b]pyrazine compounds as modulators of tyrosine kinases | AETERNA ZENTARIS GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-20090275534-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | ZENTARIS GMBH (DE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275534-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | ZENTARIS GMBH (DE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275534-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | ZENTARIS GMBH (DE) | 2009-11-05 | — | — | US | disclosed |
| WO-2008138878-A2 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | ÆTERNA ZENTARIS GMBH (DE) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275534-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | PNPO, PDXK, MKI67 | MEN1 1842/4885KMT2A 2378/4885BRAF 52/4885 |
| US-20120277219-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | PNPO, PDXK, MKI67 | MEN1 1842/4885KMT2A 2378/4885BRAF 52/4885 |
| US-20120209050-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | PNPO, PDXK, MKI67 | MEN1 1842/4885KMT2A 2378/4885BRAF 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.